DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Blood Pressure and Glucose Lowering for the Prevention of Vascular Disease in High Risk Patients With Type 2 Diabetes

Information source: The George Institute
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Diabetes Mellitus, Type 2

Intervention: Perindopril-indapamide (Drug); Gliclazide MR-based glucose lowering (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: The George Institute

Official(s) and/or principal investigator(s):
John Chalmers, MB BS PhD, Principal Investigator, Affiliation: The George Institute
Stephen W MacMahon, BSc PhD MPH, Principal Investigator, Affiliation: The George Institute


The purpose of this study is to provide information on the risks and benefits of routine blood pressure lowering (regardless of blood pressure level), and intensive lowering of blood glucose levels, in patients with Type 2 diabetes at high risk of cardiovascular events. The major outcomes of the study will be cardiovascular events (heart attack, stroke or dying as a result of cardiovascular disease), as well as new or worsening diabetic eye and kidney disease.

Clinical Details

Official title: ADVANCE - Action in Diabetes and Vascular Disease: Preterax and Diamicron - MR Controlled Evaluation

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Prevention

Primary outcome:

Composite of non-fatal stroke, non-fatal myocardial infarction or death from any cardiovascular cause

Composite of new or substantially worsening nephropathy or microvascular eye disease.

Secondary outcome: Includes cerebrovascular disease, coronary heart disease, heart failure, peripheral vascular disease, cardiovascular and all-cause mortality, microalbuminuria, visual deterioration, new or worsening nephropathy, cognitive function, and dementia.

Detailed description: Patients with type 2 diabetes are at increased risks of macrovascular and microvascular disease, both of which are reduced by control of raised blood pressure in hypertensive individuals. Intensive glycaemic control has also been shown to reduce microvascular disease, but the effects on macrovascular disease remain uncertain. This study will examine the hypotheses that blood pressure lowering (with an ACE inhibitor-diuretic combination) and intensive glycaemic control (with a sulphonylurea-based regimen) in high-risk individuals with type 2 diabetes (including hypertensive and non-hypertensive subjects) reduces the incidence of both macrovascular and microvascular disease. The study is a 2 x 2 factorial randomised controlled trial that includes 11,140 adults with type 2 diabetes at elevated risk of vascular disease. Following 6 weeks on open label perindopril-indapamide combination, eligible individuals were randomised to continued perindopril-indapamide or matching placebo, and to an intensive gliclazide MR-based glucose control regimen (aiming for HbA1c of 6. 5% or lower) or usual guidelines-based therapy. Primary outcomes are, first, the composite of non-fatal stroke, non-fatal myocardial infarction or cardiovascular death and, second, the composite of new or worsening nephropathy or diabetic eye disease. These primary outcomes will be analysed jointly and separately. The average duration of treatment and follow-up is 5. 5 to 6 years. The study is being conducted in 214 centres in Australasia, Asia, Europe and North America. ADVANCE is designed to provide reliable evidence about the balance of benefits and risks conferred by blood pressure lowering therapy and intensive glucose control therapy in high-risk diabetic patients, irrespective of initial blood pressure or glucose levels.


Minimum age: 55 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria: 1. A diagnosis of type 2 diabetes mellitus first made at age 30 years or older 2. Age 55 years or older at entry 3. Ability to provide informed consent 4. A substantially elevated risk of cardiovascular disease, indicated by:

- A history of major macrovascular disease defined as any one of: stroke,

myocardial infarction, hospital admission for transient ischaemic attack, hospital admission for unstable angina, coronary artery bypass graft, percutaneous transluminal coronary angioplasty (with or without stenting), peripheral revascularisation (angioplasty or surgery) or amputation secondary to vascular disease or

- A history of major microvascular disease defined as any one of nephropathy

(albumin: creatinine ratio >300ug/mg), retinal photocoagulation therapy, proliferative retinopathy (new blood vessels on the disc or elsewhere, vitreous haemorrhage, pre-retinal haemorrhage, or fibrous proliferations on the disc or elsewhere), macular oedema (retinal thickening within one disc diameter of the macular centre) or blindness in either eye (corrected visual acuity 6/60 or worse, persisting for three months or more) not known to be due to non-diabetic causes or

- A first diagnosis of type 2 diabetes made 10 or more years prior to entry or

- Another major risk factor for vascular disease defined as any one of: current

daily cigarette smoking, total cholesterol greater than 6. 0 mmol/l (with or without cholesterol lowering treatment), HDL cholesterol <1. 0 mmol/l, microalbuminuria (albumin: creatinine ratio 30-300ug/mg) or

- Age 65 years or over

Exclusion Criteria: 1. A definite contraindication to treatment with an ACE inhibitor or a thiazide-like diuretic 2. A specific indication for treatment with an ACE inhibitor other than perindopril 2-4 mg daily (see also section 5. 2.3) or a thiazide-like diuretic 3. A definite and specific indication for treatment with gliclazide or a haemoglobin A1c control target of 6. 5% or less 4. A definite contra-indication to treatment with gliclazide or a haemoglobin A1c control target of 6. 5% or less 5. A definite indication for long-term full-dose or bed-time insulin therapy 6. Participation in a trial within the month prior to the Registration Visit or current participation in another trial Other potential reasons for ineligibility include:

- High probability of non-adherence to study treatment or follow-up

- Current clinical instability (e. g. a major cerebral or coronary event or

sight-threatening retinopathy or macular oedema within the previous few weeks)

- Life threatening non-vascular disease other than diabetes and its complications

- Moderate or severe dementia

- Major disability that is likely to prevent regular attendance at study clinics

Final decisions about eligibility were made at the discretion of the study investigator and the potential study participant, in the light of any requirements or guidance from local ethics committees and other regulatory bodies.

Locations and Contacts

The Julius Center for Health Sciences and Primary Care, Utrecht 3508 BA, Netherlands

Imperial College School of Medicine, London W2 1PG, United Kingdom

Cardiovascular Institute & Fu Wai Hospital, Xicheng District, Beijing 100037, China

University of Montreal, Montreal, Quebec H26 1X2, Canada

The University of Melbourne, Melbourne, Victoria 3010, Australia

Additional Information

Study web page

Sponsor's web page

Related publications:

Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high-risk individuals with type 2 diabetes mellitus. Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified-Release Controlled Evaluation. J Hypertens Suppl. 2001 Nov;19(4):S21-8.

ADVANCE Collaborative Group. ADVANCE--Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline. Diabet Med. 2005 Jul;22(7):882-8.

ADVANCE Management Committee. Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicron MR controlled evaluation. Diabetologia. 2001 Sep;44(9):1118-20.

Starting date: June 2001
Last updated: September 16, 2008

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017